AU2337499A - Method for treating inflammatory diseases using heat shock proteins - Google Patents

Method for treating inflammatory diseases using heat shock proteins Download PDF

Info

Publication number
AU2337499A
AU2337499A AU23374/99A AU2337499A AU2337499A AU 2337499 A AU2337499 A AU 2337499A AU 23374/99 A AU23374/99 A AU 23374/99A AU 2337499 A AU2337499 A AU 2337499A AU 2337499 A AU2337499 A AU 2337499A
Authority
AU
Australia
Prior art keywords
heat shock
shock protein
mammal
disease
hsp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU23374/99A
Other languages
English (en)
Inventor
Erwin W. Gelfand
Angela Francisca Haczku
Katalin Veronika Lukacs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Jewish Health
Original Assignee
National Jewish Medical and Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Jewish Medical and Research Center filed Critical National Jewish Medical and Research Center
Publication of AU2337499A publication Critical patent/AU2337499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU23374/99A 1998-01-23 1999-01-22 Method for treating inflammatory diseases using heat shock proteins Abandoned AU2337499A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1233098A 1998-01-23 1998-01-23
US09012330 1998-01-23
PCT/US1999/001421 WO1999037319A1 (en) 1998-01-23 1999-01-22 Method for treating inflammatory diseases using heat shock proteins

Publications (1)

Publication Number Publication Date
AU2337499A true AU2337499A (en) 1999-08-09

Family

ID=21754459

Family Applications (1)

Application Number Title Priority Date Filing Date
AU23374/99A Abandoned AU2337499A (en) 1998-01-23 1999-01-22 Method for treating inflammatory diseases using heat shock proteins

Country Status (16)

Country Link
US (2) US20020006410A1 (https=)
EP (1) EP1049483A1 (https=)
JP (1) JP2002509074A (https=)
KR (1) KR20010040389A (https=)
CN (1) CN1324243A (https=)
AU (1) AU2337499A (https=)
BR (1) BR9907228A (https=)
CA (1) CA2318263A1 (https=)
CZ (1) CZ20002669A3 (https=)
HU (1) HUP0100241A2 (https=)
IL (1) IL137404A0 (https=)
NO (1) NO20003775L (https=)
PL (1) PL342166A1 (https=)
TR (1) TR200002973T2 (https=)
WO (1) WO1999037319A1 (https=)
ZA (1) ZA99499B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7992572B2 (en) 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
AU3239400A (en) * 1999-02-22 2000-09-04 University Of Iowa Research Foundation, The Method for inhibiting inflammatory responses
WO2001022816A1 (en) * 1999-09-30 2001-04-05 National Jewish Medical And Research Center MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
EP1551957A4 (en) * 2001-10-01 2007-01-24 Univ Duke ISOLATED POLYPEPTIDE OF THE GRP94 LIGANDEN BINDING DOMAIN AND NUCLEIC ACID, CRYSTALLINE FORM THEREOF, CODING THEREOF, AND SCRAPPING METHOD WHERE IT IS USED
WO2003068941A2 (en) * 2002-02-13 2003-08-21 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
KR100615389B1 (ko) * 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
US20100111927A1 (en) * 2002-08-23 2010-05-06 Sunyoung Kim Compositions Comprising Actinidia and Methods of Use Thereof
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
CN101330922A (zh) * 2005-10-20 2008-12-24 悉生物有限公司 超敏的治疗
KR100768265B1 (ko) * 2005-11-10 2007-10-17 한국화학연구원 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법
AU2009262670B2 (en) 2008-06-26 2013-06-20 Zevra Denmark A/S Use of Hsp70 as a regulator of enzymatic activity
WO2010086418A1 (en) * 2009-01-29 2010-08-05 Alfa Biogene International B.V. Functional food product comprising heat shock protein or a hydrolysate thereof
EP2397074B1 (en) 2010-06-19 2012-10-24 M Stenqvist AB A system and computer readable medium for determination of transpulmonary pressure in a patient connected to a breathing apparatus
CA2817773A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
WO2012097255A2 (en) * 2011-01-14 2012-07-19 Scott & White Healthcare Therapeutic effect of heat shock proteins in preventing amylin aggregation in type 2 diabetes mellitus
DK2707101T3 (da) 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
US20140228315A1 (en) * 2011-06-16 2014-08-14 Children's Hospital Medical Center Blockade of eosinophil production by toll-like receptors
US10034915B2 (en) 2011-06-23 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
CA2861464C (en) 2012-01-25 2018-03-06 Proteostasis Therapeutics, Inc. Proteasome activity modulating tricyclic compounds
AU2015317447B2 (en) 2014-09-15 2021-02-25 Zevra Denmark A/S Arimoclomol formulation
EP3402572B1 (en) 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
DK3782624T3 (da) 2016-04-29 2025-12-15 Zevra Denmark As Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
CN106220718B (zh) * 2016-08-04 2019-12-10 上海市农业科学院 一种草菇热激蛋白VvHSP60及其应用
CN106243203B (zh) * 2016-08-04 2019-12-10 上海市农业科学院 一种草菇热激蛋白VvHSP70及其应用
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
EP3781588B1 (en) 2018-04-20 2024-10-30 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
CN112585130A (zh) 2018-06-27 2021-03-30 蛋白质平衡治疗股份有限公司 蛋白酶体活性增强化合物
BR112020026580A2 (pt) 2018-06-27 2021-03-23 Proteostasis Therapeutics, Inc. (Fem) Compostos, composição farmacêutica e métodos para tratar um paciente
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
CN114046596B (zh) * 2021-11-17 2022-09-23 重庆大学 基于trp生化指标检测的室内空气质量控制系统及方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
CA2095855C (en) * 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens
GB9211736D0 (en) * 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
JP4484969B2 (ja) * 1996-11-26 2010-06-16 ヌベンタ バイオファーマスティカル コーポレイション ストレスタンパク質を含む組成物を使用する免疫応答

Also Published As

Publication number Publication date
CN1324243A (zh) 2001-11-28
HUP0100241A2 (hu) 2001-06-28
ZA99499B (en) 1999-07-22
US20070179087A1 (en) 2007-08-02
EP1049483A1 (en) 2000-11-08
CA2318263A1 (en) 1999-07-29
IL137404A0 (en) 2001-07-24
NO20003775L (no) 2000-09-22
CZ20002669A3 (cs) 2001-11-14
WO1999037319A1 (en) 1999-07-29
PL342166A1 (en) 2001-05-21
JP2002509074A (ja) 2002-03-26
KR20010040389A (ko) 2001-05-15
BR9907228A (pt) 2000-10-24
TR200002973T2 (tr) 2001-02-21
US20020006410A1 (en) 2002-01-17
NO20003775D0 (no) 2000-07-21

Similar Documents

Publication Publication Date Title
US20020006410A1 (en) Method for treating inflammatory diseases using heat shock proteins
Moller et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis
US5906815A (en) Treatment for diseases involving inflammation
Smaldone Repurposing of gamma interferon via inhalation delivery
Miyahara et al. IL-13 is essential to the late-phase response in allergic rhinitis
US20120148532A1 (en) Method of treating pulmonary disease with interferons
US20240076393A1 (en) Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor
US6248723B1 (en) Method for treatment of inflammatory disease
Li et al. Therapeutic effects of DNA vaccine on allergen-induced allergic airway inflammation in mouse model
Ming et al. The effect of inhaled inactived Mycobacterium phlei as a treatment for asthma
US20020141995A1 (en) Method for treatment of inflammatory disease
Yan et al. The establishment of humanized IL-4/IL-4RA mouse model by gene editing and efficacy evaluation
MXPA00007148A (es) Metodo para el tratamiento de enfermedades inflamatorias usando proteinas de choque termico
JP5175198B2 (ja) インターフェロンを用いる肺疾患の処置方法
AU2001245453B2 (en) Method and composition for treating airway hyperresponsiveness
US8105571B2 (en) Method of treating pulmonary disease with interferons
Grzela et al. Protein-based strategies of molecular therapy in allergy
JP2012193207A (ja) インターフェロンを用いる肺疾患の処置方法
Horiba et al. Low-dose exogenous interleukin (IL)-12 enhances antigen-induced interferon-γ production without affecting IL-10 production in asthmatics
US20010046955A1 (en) Method for reducing allergen-induced airway hyperresponsiveness
JP2015057446A (ja) インターフェロンを用いる肺疾患の処置方法

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted